Markets:
DJIA --204.730.66%
NASDAQ --32.430.24%
S&P --16.150.42%
Featured Stocks:
HBP 0.29% 3.45
IWM 0.49% 211.48
SOCL +0.79% 67.67
IIPR -2.26% 192.21

pharmaceutical stocks to buy

Article Index

These Pharmaceutical Stocks Let You Tap into a $402 Billion Trend

By , Associate Editor, Money Morning • @KyleAndersonMM -

pharmaceutical stocks

A sector of the pharmaceutical market known as "high-margin specialty drugs" is presenting us with the best pharmaceutical stocks to buy now.

According to experts at PricewaterhouseCoopers, consumer spending on high-margin specialty drugs hit $87.1 billion in 2012. In five years that number will quadruple to $401.7 billion.

The Wall Street Journal reports that total U.S. prescription drug spending was just $325.7 billion in 2012.

And those aren't the only alarming growth numbers boosting pharma stocks now...

Some of the Best Pharma Stocks to Buy Now Are in This Overlooked Sector

By , Associate Editor, Money Morning • @KyleAndersonMM -

There's nothing wrong with Big Pharma stocks, but investors need to realize they're not the only game in town. We're talking about a group of pharmaceutical stocks that possess an astounding 80% of the prescription drug market.

According to Money Morning’s BioScience Investment Specialist Ernie Tremblay, this group is an extremely profitable, and simple, way to play the pharmaceutical industry.

And yet these stocks often get overlooked...

The BioScience Profit Outlook for the Rest of 2014

By , Biotech Investing Specialist, Money Morning -

With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second half of 2014. There are huge opportunities in several subsectors of the bioscience market in particular.

That said, some bioscience analysts are saying there's a bubble. And it's scaring a lot of bioscience investors out of great positions in the market.

That's why last week I shared my complete bioscience market outlook for the rest of 2014 with my paid members - to help them see the real market story.

Today I want to share with you some of my thinking, expectations, and predictions, as well as my strategy to get us tapped in to a segment of the bioscience market we haven't even touched yet.

This segment has been tremendously profitable for some of the world's biggest drug companies, and I think there are going to be some killer profits for us there, too... Full Story